Welcome back to another edition of Endpoints Weekly! While it is still technically summer, the season is starting to turn now ...

Cal­i­for­nia-based drug de­vel­op­er Ex­elix­is sub­mit­ted new safe­ty and ef­fi­ca­cy da­ta on its po­ten­tial treat­ment of metasta­t­ic col­orec­tal can­cer (mCRC) to the FDA. The new da­ta led ...

Alzheon, a biotech that has been attempting to treat Alzheimer's with a checkered drug candidate for more than a decade, is ...

Yarrow Bioscience raises $150M; AbbVie's Qulipta succeeds in Phase 3 menstrual migraine trial; Sino Biopharm pays $668M for 5 ...

Andy Plump's upcoming retirement marks another major change to Takeda's leadership team after Christophe Weber handed the keys to Julie Kim.

The findings underscore one of the hard truths of the US drug market: Cheaper options can only reach patients if they’re made ...

Oura's S-1 lays out a push beyond wellness into healthcare, with $1.21B in nine-month revenue and FDA device regulation as a ...

Compass psilocybin drug reports 13-pt reduction in depression score; Solstice debuts with $225M Series A; Luma unveils $410M ...

Endpoints News reviews 77 E11 startups; highlights include Candid's $2B UCB buyout, Isomorphic Labs' $2.1B raise, Orca Bio's ...

BridgeBio Oncology's stock drops 24% as it narrows BBO-8520 to 2L+ NSCLC, trimming its broader KRAS pipeline plans.

Lonza breaks ground on an Oregon spray-drying plant, Samsung Bio lands a $262M deal, and Boston Scientific restores supply post-cyberattack.

The precision genetic medicine biotech also said it hopes to grow its manufacturing footprint and launch another program into ...